Attentive Science — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Attentive Science is a preclinical-stage contract research organization (CRO) leveraging operational expertise and a client-centric model to support drug development across multiple industries. Its core offerings include in-vivo pharmacokinetics, regulatory toxicology, and safety pharmacology studies, with an emphasis on transparent communication and digital tools like virtual facility tours. While positioned in the AI/ML and digital health sectors, its current business appears focused on providing research services rather than developing its own proprietary therapeutic pipeline.

Digital HealthAI / Machine Learning

Technology Platform

Integrated preclinical research service platform combining scientific expertise, in-vivo test systems, standardized protocols, and reporting infrastructure, with an implied focus on data-driven and potentially AI-enhanced study execution and analysis.

Opportunities

The growing trend of outsourcing in biopharma R&D and the increasing complexity of novel drug modalities (e.g., gene therapies) create strong demand for specialized preclinical CRO services.

Differentiating through a superior client experience, digital engagement, and operational excellence in high-need areas like regulatory toxicology presents a significant growth opportunity.

Risk Factors

Intense competition from large, established CROs and niche players poses a market share challenge.

Operational risks related to the consistent, high-quality execution of regulated studies are critical, as any failure could severely damage the young company's reputation.

There is a risk that its AI/ML sector positioning may not translate into a tangible competitive advantage if not fully realized in its service offerings.

Competitive Landscape

Attentive Science competes in the fragmented preclinical CRO market against giants like Charles River Laboratories and Labcorp, as well as many mid-sized and specialty CROs. Its competitive strategy appears to be based on superior client service, cultural focus, and operational attentiveness rather than scale, targeting sponsors who value close collaboration over the breadth of a global provider.

More companies in Small Molecule Drugs →More companies in United States →